Thus, GR inhibition decreases ADPC and CRPC prostate cancer cell growth and enhances the cell growth inhibitory effect of enzalutamide (Figure 4H, I, Supplementary Figure S11, S17) ((23,43,51,52). Here, NR3C1 is linked to prostate cancer.